scholarly journals Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study

2019 ◽  
Vol 8 (10) ◽  
pp. 1590 ◽  
Author(s):  
Majewski ◽  
Szewczyk ◽  
Białas ◽  
Miłkowska-Dymanowska ◽  
Górski ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Antifibrotic Therapy ◽  
Lung Compartment ◽  
Before And After ◽  
One Year ◽  
Study Participants

Background: Recently, epithelial alarmins have been shown to play important roles in non-allergen driven respiratory diseases like idiopathic pulmonary fibrosis (IPF). Little is known about the expression of the epithelial alarmins in IPF. Methods: This study aimed to prospectively examine interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP) levels in the serum and exhaled breath condensate (EBC) in patients with IPF before and after one-year of antifibrotic treatment. A total of 82 volunteers, including 52 patients diagnosed with IPF that qualified for antifibrotic therapy as well as 30 controls, were examined. All study participants underwent baseline peripheral blood and EBC sampling. In 35 out of 52 IPF subjects, a follow-up sampling was performed after 12 months of antifibrotic treatment. Concentrations of alarmins in the serum and EBC were evaluated by means of ELISA. Results: Baseline TSLP concentrations were significantly elevated in patients with IPF compared to controls both in the serum (p < 0.05) and EBC (p < 0.0001). Baseline IL-25 and IL-33 serum and EBC levels did not differ significantly between IPF subjects and controls. Prospective analysis of changes in the epithelial alarmin levels showed significantly decreased IL-25 and TSLP EBC concentrations after 12 months of antifibrotic treatment (p < 0.05), which was observed in the subgroup of IPF patients treated with pirfenidone, but not in those treated with nintedanib. In stable patients with IPF over a study period (absolute forced vital capacity (FVC) % of predicted decline/year ≤ 5%, n = 25), a significant decrease in the EBC levels of both IL-25 and TSLP after 12 months of antifibrotic treatment was noted (p < 0.05), whereas, in progressor IPF patients (absolute FVC % of predicted decline/year > 5%, n = 10), a significant decrease was noted in the IL-25 EBC levels only (p < 0.05). Conclusions: Elevated TSLP levels in patients with IPF and their significant decrease in the lung compartment during antifibrotic therapy in stable patients with IPF, but not in progressors, support its significant contribution to pro-fibrotic type 2 immune responses in IPF. Noted changes in the epithelial alarmins concentration in the lung compartment during pirfenidone therapy may suggest its possible interaction with epithelial alarmins pathways in IPF.

Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis

2018 ◽  
Author(s):  
Sebastian Majewski ◽  
Damian Tworek ◽  
Karolina Szewczyk ◽  
Zofia Kurmanowska ◽  
Adam Antczak ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

scholarly journals Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Cells ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 143
Author(s):  
Kazutaka Takehara ◽  
Yasuhiko Koga ◽  
Yoshimasa Hachisu ◽  
Mitsuyoshi Utsugi ◽  
Yuri Sawada ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Adverse Events ◽  
Disease Progression ◽  
Continuous Treatment ◽  
Discontinuation Rate ◽  
Antifibrotic Therapy ◽  
Significant Difference ◽  
One Year ◽  
Observation Period

Antifibrotic agents have been widely used in patients with idiopathic pulmonary fibrosis (IPF). Long-term continuation of antifibrotic therapy is required for IPF treatment to prevent disease progression. However, antifibrotic treatment has considerable adverse events, and the continuation of treatment is uncertain in many cases. Therefore, we examined and compared the continuity of treatment between pirfenidone and nintedanib in patients with IPF. We retrospectively enrolled 261 consecutive IPF patients who received antifibrotic treatment from six core facilities in Gunma Prefecture from 2009 to 2018. Among them, 77 patients were excluded if the antifibrotic agent was switched or if the observation period was less than a year. In this study, 134 patients treated with pirfenidone and 50 treated with nintedanib were analyzed. There was no significant difference in patient background, discontinuation rate of antifibrotic treatment over time, and survival rate between the two groups. However, the discontinuation rate due to adverse events within one year of antifibrotic treatment was significantly higher in the nintedanib group than in the pirfenidone group (76% vs. 37%, p < 0.001). Furthermore, the discontinuation rate due to adverse events in nintedanib was higher than that of pirfenidone treatment throughout the observation period (70.6% vs. 31.2%, p = 0.016). The pirfenidone group tended to be discontinued due to acute exacerbation or transfer to another facility. The results of this study suggest that better management of adverse events with nintedanib leads to more continuous treatment that prevents disease progression and acute exacerbations, thus improving prognosis in patients with IPF.

scholarly journals Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis—a pilot study

2017 ◽  
Vol 12 (1) ◽  
pp. 016003 ◽  
Author(s):  
Barbara Rindlisbacher ◽  
Carina Strebel ◽  
Sabina Guler ◽  
Attila Kollár ◽  
Thomas Geiser ◽  
...  
Keyword(s):  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Potential Biomarker ◽  
Breath Condensate

scholarly journals Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis

2010 ◽  
Vol 24 (5) ◽  
pp. 317-322 ◽  
Author(s):  
Vladimír Rihák ◽  
Petr Zatloukal ◽  
Jirina Chládková ◽  
Alena Zimulová ◽  
Zuzana Havlínová ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

scholarly journals Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review

2020 ◽  
Vol 29 (157) ◽  
pp. 190158 ◽  
Author(s):  
Yet H. Khor ◽  
Yvonne Ng ◽  
Hayley Barnes ◽  
Nicole S.L. Goh ◽  
Christine F. McDonald ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Cohort Studies ◽  
Vital Capacity ◽  
Healthcare Delivery ◽  
Comprehensive Information ◽  
Delivery Planning ◽  
Randomised Controlled ◽  
Study Participants

In addition to facilitating healthcare delivery planning, reliable information about prognosis is essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This review aimed to evaluate the prognosis of patients with IPF without anti-fibrotic therapy. We included all cohort studies and the placebo arms of randomised controlled trials (RCTs) in IPF and follow-up of ≥12 months. Two reviewers independently evaluated studies for inclusion, assessed risk of bias and extracted data. A total of 154 cohort studies and 16 RCTs were included. The pooled proportions of mortality were 0.12 (95% CI 0.09–0.14) at 1–2 years, 0.38 (95% CI 0.34–0.42) between 2–5 years, and 0.69 (95% CI 0.59–0.78) at ≥5 years. The pooled mean overall survival was 4 years (95% CI 3.7–4.6) for studies with a follow-up duration of 10 years. At <2 years, forced vital capacity and diffusing capacity of the lung for carbon monoxide declined by a mean of 6.76% predicted (95% CI −8.92 −4.61) and 3% predicted (95% CI −5.14 −1.52), respectively. Although heterogeneity was high, subgroup analyses revealed lower pooled proportions of mortality at 1 year in the RCT participants (0.07 (95% CI 0.05–0.09)) versus cohort study participants (0.14 (95% CI 0.12–0.17)). This review provides comprehensive information on the prognosis of IPF, which can inform treatment discussions with patients and comparisons for future studies with new therapies.

scholarly journals Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Sydney B Montesi ◽  
Susan K Mathai ◽  
Laura N Brenner ◽  
Irina A Gorshkova ◽  
Evgeny V Berdyshev ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

scholarly journals Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis—A Six-Month Follow-up Study in Patients Treated with Pirfenidone

2020 ◽  
Vol 9 (8) ◽  
pp. 2523
Author(s):  
Kaja Jaskiewicz ◽  
Katarzyna Mycroft ◽  
Marta Maskey-Warzechowska ◽  
Karolina Paralusz ◽  
Natalia Siemiez ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
High Sensitivity ◽  
Cytokine Profile ◽  
Exhaled Breath ◽  
Vascular Endothelial ◽  
Tnf Α ◽  
Cytokine Levels ◽  
Endothelial Growth Factor

The mechanism of action of pirfenidone in idiopathic pulmonary fibrosis (IPF) has not been fully elucidated. To offer additional insight, we evaluated the change in the cytokine profile in exhaled breath condensate (EBC) following a six-month treatment with pirfenidone in patients with IPF. EBC concentrations of interleukin (IL)-6, IL-8, IL-15, TNF-α and VEGF-A were assessed with ELISA and compared at baseline and after six months of pirfenidone treatment. Twenty-nine patients with IPF and 13 controls were evaluated at baseline. With the exception of IL-8 concentration, which was lower in patients with IPF when compared to controls (p = 0.005), the cytokine levels did not differ between the groups. Despite the use of a high sensitivity assay, IL-8 reached detectable values only in 24% of IPF patients. EBC analysis after six months of treatment with pirfenidone did not reveal any differences in the cytokine levels. The change in EBC vascular endothelial growth factor A (VEGF-A) correlated with the change in the 6 min walk distance (r = 0.54, p = 0.045). We conclude that a six-month treatment with pirfenidone did not significantly change the EBC cytokine profile. Our findings support the potential usefulness of VEGF-A as a marker in IPF. The low EBC IL-8 level in patients with IPF is a novel finding which needs confirmation in larger studies.

Exhaled breath condensate - a new tool for assessment of idiopathic pulmonary fibrosis?

2018 ◽  
Author(s):  
Natalia Przysucha ◽  
Katarzyna Gorska ◽  
Magdalena Paplinska ◽  
Patrycja Nejman-Gryz ◽  
Magdalena Proboszcz ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate
Sign in / Sign up

Export Citation Format

Share Document